AstraZeneca logo displayed on glass office building facade

PARTNERSHIPS

10 Feb 2026

AstraZeneca Bets on AI to Rethink Obesity Care

AstraZeneca and CSPC join forces, blending AI and long-acting dosing to speed new obesity and diabetes drugs across global markets

Close-up of GLP-1 text under magnifying glass with obesity and diabetes terms

MARKET TRENDS

5 Feb 2026

Patients Take the Lead in US Metabolic Drug Pricing

Patients, not just policymakers or drugmakers, are reshaping access and pricing in the fast-growing US metabolic therapy market

AstraZeneca logo on pharmaceutical company headquarters

PARTNERSHIPS

3 Feb 2026

AstraZeneca Brings AI In-House to Speed Drug Discovery

AstraZeneca acquires Modella AI to embed data and AI directly into research, signaling how central artificial intelligence has become to m...

Clinician reviewing laboratory data beside test tubes in medical research setting

RESEARCH

30 Jan 2026

New Metabolic Data Reignite Interest in Liver-Targeted Lipid Drugs

Early clinical data revive a sidelined liver pathway, drawing fresh attention while leaving Phase 2 results as the real test

Illustration of a human liver showing cellular damage linked to metabolic disease

PARTNERSHIPS

20 Jan 2026

Roche’s 89bio Deal Heats Up the Race for MASH Drugs

Roche’s acquisition of 89bio signals rising confidence in late-stage MASH drugs and sharpens competition for metabolic liver disease treat...

Laboratory researcher pipetting samples during obesity drug development research

INSIGHTS

19 Jan 2026

A $160M Biotech Bet Points to Obesity Drugs’ Next Test

A newly funded startup is betting durability, not just weight loss, will define the next era of obesity drugs

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.